2021 | Recurrent Myocarditis Induced by Immune-Checkpoint Inhibitor Treatment Is Accompanied by Persistent Inflammatory Markers Despite Immunosuppressive Treatment
https://pmccbiobank.ca/wp-content/themes/osmosis/images/empty/thumbnail.jpg 150 150 admpmccbiobank admpmccbiobank https://secure.gravatar.com/avatar/0f296d05bd552e6f703c803312c7ef39?s=96&d=mm&r=g
Authors: Nazanian Aghel, Dakota Gustafson, Ashley Di Meo, Milena Music, Ioannis Prassas, Michael A. Seidman, Aaron R. Hansen, Paaladinesh Thavendiranathan, Eleftherios P. Diamandis, Diego Delgado, Jason E. Fish
Short Description: A case report of recurrent myocarditis in a patient previously treated with a programmed death ligand I inhibitor, an immune checkpoint inhibitor that blocks the binding of PD-L1 to programmed cell death protein 1 and CD80.
Interest: Cancer, Cardio-Oncology, Cardiology, Heart disease, Myocarditis